MIGRAINE prevention with galcanezumab showed higher 3 month response rates than oral therapies in Japanese clinical practice, according to interim subgroup findings from the TRIUMPH study.
In this real world, prospective, observational analysis, adults with migraine either initiated or switched to galcanezumab or traditional oral migraine preventive medications. The Japan subgroup included 846 patients, with 469 receiving galcanezumab and 377 receiving traditional oral therapies. Investigators assessed clinically meaningful response at 3 months, defined as at least a 50% reduction in monthly migraine headache days for episodic migraine and at least a 30% reduction for chronic migraine.
Galcanezumab Migraine Prevention Results at 3 Months
At 3 months, the weighted response rate was 59.4% in the galcanezumab group versus 38.3% in the oral preventive group. Mean monthly migraine headache days fell by 6.2 days with galcanezumab compared with 4.2 days with traditional oral migraine preventive medications.
The study also examined several patient reported outcomes that capture disability, daily burden, quality of life, and work impairment. These included MIDAS, HIT 6, MIBS 4, MSQv2.1, and WPAI. Across all of these measures, the mean change from baseline at 3 months was numerically greater with galcanezumab than with oral preventive therapies, pointing to broader clinical benefit beyond headache day reduction alone.
What the Migraine Findings Mean for Practice
These findings add useful real world evidence for clinicians weighing preventive treatment choices in migraine care. Because treatment decisions were made during routine practice rather than assigned by protocol, the results may better reflect the kinds of decisions and outcomes seen in everyday neurology settings.
The analysis used inverse probability of treatment weighting to adjust for baseline differences between groups. However, no alpha was allocated for formal comparative testing, so the results should be interpreted as numerical differences rather than definitive superiority testing.
Even so, the pattern is clinically relevant. Early improvement in monthly migraine headache days, alongside numerically better patient reported outcomes, suggests galcanezumab may offer stronger short term effectiveness for some patients than traditional oral migraine preventive medications. The authors noted that these interim findings may help guide physician decision making in real world clinical settings.
Reference
Takeshima T et al. Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study. Advances in Therapy. 2026;DOI:10.1007/s12325-026-03588-2.
Featured Image: Studio Romantic on Adobe Stock.
